Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Sold by Creative Planning

Creative Planning decreased its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 1.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,615 shares of the company’s stock after selling 47 shares during the period. Creative Planning’s holdings in Medpace were worth $1,540,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in MEDP. Fidelis Capital Partners LLC purchased a new stake in shares of Medpace during the first quarter worth about $31,000. J.Safra Asset Management Corp grew its stake in Medpace by 87.0% during the 1st quarter. J.Safra Asset Management Corp now owns 101 shares of the company’s stock valued at $41,000 after purchasing an additional 47 shares in the last quarter. DT Investment Partners LLC purchased a new stake in Medpace during the 2nd quarter worth approximately $41,000. Ashton Thomas Private Wealth LLC acquired a new position in shares of Medpace in the 2nd quarter valued at approximately $52,000. Finally, EntryPoint Capital LLC purchased a new position in shares of Medpace during the 1st quarter valued at approximately $54,000. Institutional investors and hedge funds own 77.98% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently issued reports on MEDP. Redburn Atlantic started coverage on shares of Medpace in a research note on Monday, October 14th. They issued a “buy” rating and a $404.00 price target for the company. Robert W. Baird downgraded shares of Medpace from an “outperform” rating to a “neutral” rating and dropped their target price for the stock from $413.00 to $349.00 in a research report on Wednesday, October 23rd. Deutsche Bank Aktiengesellschaft cut their target price on shares of Medpace from $395.00 to $336.00 and set a “hold” rating on the stock in a research note on Wednesday, July 24th. William Blair reiterated an “outperform” rating on shares of Medpace in a research note on Tuesday, October 22nd. Finally, Baird R W lowered Medpace from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 23rd. Seven equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $380.00.

Medpace Stock Up 0.1 %

Shares of MEDP stock opened at $329.76 on Wednesday. The company has a market cap of $10.22 billion, a P/E ratio of 33.61, a PEG ratio of 1.74 and a beta of 1.35. The business has a 50 day moving average of $349.01 and a two-hundred day moving average of $380.03. Medpace Holdings, Inc. has a 52 week low of $239.00 and a 52 week high of $459.77.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Monday, October 21st. The company reported $3.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.77 by $0.24. Medpace had a return on equity of 50.87% and a net margin of 17.66%. The business had revenue of $533.32 million during the quarter, compared to analyst estimates of $540.99 million. During the same quarter in the previous year, the firm posted $2.22 EPS. The business’s revenue for the quarter was up 8.3% compared to the same quarter last year. Analysts expect that Medpace Holdings, Inc. will post 11.77 EPS for the current fiscal year.

Medpace Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.